Journal: Frontiers in Nutrition

Article Title: Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet

doi: 10.3389/fnut.2022.971581

Figure Lengend Snippet: The primers used for the polymerase chain reaction (PCR) reaction.

Article Snippet: Then, the membranes were blotted with the corresponding primary and secondary antibodies listed as follows: a mouse monoclonal antibody against SREBP-1c (2A4) (SANTA CRUZ, USA, sc-13551, 1:500), a rabbit polyclonal antibody against PPARγ (Proteintech, USA, 16643-1-AP, 1:1000), a mouse monoclonal antibody against PPARα (Abcam, USA, ab97609, 1:800), a mouse monoclonal antibody against β-actin (Abcam, USA, ab8226, 1:1000), a rabbit polyclonal antibody against LDLR (Abcam, USA, ab30532, 1:200), and secondary antibodies including a goat anti-rabbit IgG H&L (HRP) (Abcam, USA, ab6721, 1:3000) and a goat anti-mouse IgG H&L (HRP) (Abcam, USA, ab205719, 1:5000).

Techniques: Polymerase Chain Reaction

Journal: Frontiers in Nutrition

Article Title: Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet

doi: 10.3389/fnut.2022.971581

Figure Lengend Snippet: Effect of fenofibrate on the expression of proteins involved in lipid metabolism in the plasma and liver of the ob/ob mice ( n = 6). (A) protein expression and densitometric quantification of plasma apolipoprotein (Apo) A-I; (B) protein expression and densitometric quantification of plasma Apo B; (C) protein expression and densitometric quantification of low-density lipoprotein receptor (LDLR) in the liver; (D) protein expression and densitometric quantification of peroxisome proliferator activated receptor (PPAR) α in the liver; (E) protein expression and densitometric quantification of PPARγ in the liver; (F) protein expression and densitometric quantification of sterol regulatory element binding protein (SREBP)-1c in the liver. Data were expressed as mean ± SD, and the statistical analysis was performed by Student- t -test. * means significantly different at p < 0.05 vs . Vehicle group; ** means significantly different at p < 0.01 vs . Vehicle group. Vehicle: mice were treated with 0.5 mL of water by gavage for 13 weeks; Fenofibrate: mice were treated with 0.5 mL of fenofibrate suspension liquid at the dose of 20 mg/kg/d by gavage for 13 weeks.

Article Snippet: Then, the membranes were blotted with the corresponding primary and secondary antibodies listed as follows: a mouse monoclonal antibody against SREBP-1c (2A4) (SANTA CRUZ, USA, sc-13551, 1:500), a rabbit polyclonal antibody against PPARγ (Proteintech, USA, 16643-1-AP, 1:1000), a mouse monoclonal antibody against PPARα (Abcam, USA, ab97609, 1:800), a mouse monoclonal antibody against β-actin (Abcam, USA, ab8226, 1:1000), a rabbit polyclonal antibody against LDLR (Abcam, USA, ab30532, 1:200), and secondary antibodies including a goat anti-rabbit IgG H&L (HRP) (Abcam, USA, ab6721, 1:3000) and a goat anti-mouse IgG H&L (HRP) (Abcam, USA, ab205719, 1:5000).

Techniques: Expressing, Clinical Proteomics, Binding Assay, Suspension

Journal: Frontiers in Nutrition

Article Title: Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet

doi: 10.3389/fnut.2022.971581

Figure Lengend Snippet: Effect of fenofibrate on the expression of genes involved in lipid metabolism in the liver of the ob/ob mice. Gene relative expression of (A) peroxisome proliferator activated receptor (PPAR) α ( n = 12); (B) acyl-CoA oxidase (ACOX)-1 ( n = 12); (C) carnitine palmitoyltransferase (CPT)-1α ( n = 12); (D) CPT-2 ( n = 12); (E) PPARγ ( n = 7); (F) sterol regulatory element binding protein (SREBP)−1c ( n = 9); (G) stearoyl Coenzyme A desaturase-1 (SCD-1) ( n = 4); (H) fatty acid synthase (FAS) ( n = 4). The RT-qPCR experiment was repeated for one more time to confirm the gene expression trends of PPARα, ACOX-1, CPT-1α, CPT-2, and SREBP-1c. Data were expressed as mean ± SD, and the statistical analysis was performed by Student- t -test. * means significantly different at p < 0.05 vs . Vehicle group; ** means significantly different at p < 0.01 vs . Vehicle group. Vehicle: mice were treated with 0.5 mL of water by gavage for 13 weeks; Fenofibrate: mice were treated with 0.5 mL of fenofibrate suspension liquid at the dose of 20 mg/kg/d by gavage for 13 weeks.

Article Snippet: Then, the membranes were blotted with the corresponding primary and secondary antibodies listed as follows: a mouse monoclonal antibody against SREBP-1c (2A4) (SANTA CRUZ, USA, sc-13551, 1:500), a rabbit polyclonal antibody against PPARγ (Proteintech, USA, 16643-1-AP, 1:1000), a mouse monoclonal antibody against PPARα (Abcam, USA, ab97609, 1:800), a mouse monoclonal antibody against β-actin (Abcam, USA, ab8226, 1:1000), a rabbit polyclonal antibody against LDLR (Abcam, USA, ab30532, 1:200), and secondary antibodies including a goat anti-rabbit IgG H&L (HRP) (Abcam, USA, ab6721, 1:3000) and a goat anti-mouse IgG H&L (HRP) (Abcam, USA, ab205719, 1:5000).

Techniques: Expressing, Binding Assay, Quantitative RT-PCR, Gene Expression, Suspension

Journal: Frontiers in Nutrition

Article Title: Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet

doi: 10.3389/fnut.2022.971581

Figure Lengend Snippet: Effect of fenofibrate on the fat index and expression of proteins involved in lipid metabolism in the white adipose of the ob/ob mice ( n = 6 unless otherwise specialized). (A) fat index was calculated according to the following formula: fat index = [(white adipose weight × 100%) ÷ body weight] ( n = 7 for the Vehicle group and n = 8 for the Fenofibrate group). Protein expression and densitometric quantification (B) peroxisome proliferator activated receptor (PPAR) α; (C) PPARγ; (D) sterol regulatory element binding protein (SREBP)-1c. Data were expressed as mean ± SD, and the statistical analysis was performed by Student- t -test. ** means significantly different at p < 0.01 vs . Vehicle group. Vehicle: mice were treated with 0.5 mL of water by gavage for 13 weeks; Fenofibrate: mice were treated with 0.5 mL of fenofibrate suspension liquid at the dose of 20 mg/kg/d by gavage for 13 weeks.

Article Snippet: Then, the membranes were blotted with the corresponding primary and secondary antibodies listed as follows: a mouse monoclonal antibody against SREBP-1c (2A4) (SANTA CRUZ, USA, sc-13551, 1:500), a rabbit polyclonal antibody against PPARγ (Proteintech, USA, 16643-1-AP, 1:1000), a mouse monoclonal antibody against PPARα (Abcam, USA, ab97609, 1:800), a mouse monoclonal antibody against β-actin (Abcam, USA, ab8226, 1:1000), a rabbit polyclonal antibody against LDLR (Abcam, USA, ab30532, 1:200), and secondary antibodies including a goat anti-rabbit IgG H&L (HRP) (Abcam, USA, ab6721, 1:3000) and a goat anti-mouse IgG H&L (HRP) (Abcam, USA, ab205719, 1:5000).

Techniques: Expressing, Binding Assay, Suspension

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Beneficial Effect of Taraxacum coreanum Nakai via the Activation of LKB1-AMPK Signaling Pathway on Obesity

doi: 10.1155/2021/6655599

Figure Lengend Snippet: PPAR α , UCP-2, and CPT-1 expressions in the liver of mice fed HFD. Western blot analysis of PPAR α , UCP-2, and CPT-1 proteins. Normal: normal mice; Control: HFD control mice; GCE200: GCE 200 mg/kg-treated and obese mice; TCN100: TCN 100 mg/kg-treated and obese mice; TCN200: TCN 200 mg/kg-treated and obese mice. Data are the mean ± SD ( n = 7). Significance: ∗ p < 0.05, ∗∗ p < 0.01 versus the HFD control mice. The blots shown are representative of three blots from each group of mice. PPAR α : peroxisome proliferator activated receptor α ; UCP-2: uncoupling protein 2; CPT-1: carnitine palmitoyltransferase 1A.

Article Snippet: Rabbit polyclonal antibody against peroxisome proliferator activated receptor (PPAR) α , mouse monoclonal antibodies against β -actin and histone, and goat polyclonal antibody against mitochondrial uncoupling protein (UCP)-2 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

Techniques: Western Blot, Control